Antagonist-mediated down-regulation of toll-like receptors increases the prevalence of human papillomavirus infection in systemic lupus erythematosus

[1]  P. Boor,et al.  Prednisolone Suppresses the Function and Promotes Apoptosis of Plasmacytoid Dendritic Cells , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  S. Ho,et al.  Risk factors for squamous intraepithelial lesions in systemic lupus erythematosus: A prospective cohort study , 2011, Arthritis care & research.

[3]  P. Chan,et al.  Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. , 2004, Arthritis and rheumatism.

[4]  D. Symmons,et al.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. , 1996, Arthritis and rheumatism.

[5]  T. Iftner,et al.  TLR9 Expression and Function Is Abolished by the Cervical Cancer-Associated Human Papillomavirus Type 161 , 2007, The Journal of Immunology.

[6]  G. Sen,et al.  Interferon‐inducible protein, P56, inhibits HPV DNA replication by binding to the viral protein E1 , 2008, The EMBO journal.

[7]  P. Chan,et al.  Biases in human papillomavirus genotype prevalence assessment associatedwith commonly used consensus primers , 2006, International journal of cancer.

[8]  S. Melgar,et al.  Intra-colonic administration of the TLR7 agonist R-848 induces an acute local and systemic inflammation in mice. , 2008, Biochemical and biophysical research communications.

[9]  C. Szeto,et al.  Down-Regulated NOD2 by Immunosuppressants in Peripheral Blood Cells in Patients with SLE Reduces the Muramyl Dipeptide-Induced IL-10 Production , 2011, PloS one.

[10]  V. Preedy,et al.  Prospective Cohort Study , 2010 .

[11]  C. Bruggeman,et al.  The type I interferon response during viral infections: a “SWOT” analysis , 2011, Reviews in medical virology.

[12]  H. Amano,et al.  Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus. , 2007, Rheumatology.

[13]  B. Jasani,et al.  Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer. , 2009, Vaccine.

[14]  L. Tam,et al.  Immunopathological Roles of Cytokines, Chemokines, Signaling Molecules, and Pattern-Recognition Receptors in Systemic Lupus Erythematosus , 2012, Clinical & developmental immunology.

[15]  C. Woodworth,et al.  Papillomavirus Type 16 Oncogenes Downregulate Expression of Interferon-Responsive Genes and Upregulate Proliferation-Associated and NF-κB-Responsive Genes in Cervical Keratinocytes , 2001, Journal of Virology.

[16]  M. Shlomchik,et al.  Chromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors , 2002, Nature.

[17]  K. Straif,et al.  Carcinogenicity of human papillomaviruses. , 2005, The Lancet. Oncology.

[18]  P. Chan,et al.  Determinants of cervical human papillomavirus infection: differences between high- and low-oncogenic risk types. , 2002, The Journal of infectious diseases.

[19]  L. Laimins,et al.  Microarray Analysis Identifies Interferon-Inducible Genes and Stat-1 as Major Transcriptional Targets of Human Papillomavirus Type 31 , 2000, Journal of Virology.

[20]  M. Petri,et al.  Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. , 1991, Arthritis and rheumatism.

[21]  N. Khan,et al.  Effects of age, gender, and immunosuppressive agents on in vivo toll-like receptor pathway responses. , 2010, Human immunology.

[22]  A. Komatsuda,et al.  Up‐regulated expression of Toll‐like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus , 2008, Clinical and experimental immunology.

[23]  M. Wong,et al.  Natural History of Cervical Papilloma Virus Infection in Systemic Lupus Erythematosus — A Prospective Cohort Study , 2010, The Journal of Rheumatology.

[24]  L. Manzel,et al.  Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. , 1998, Journal of immunology.

[25]  L. Tam,et al.  Effects of inflammatory cytokine IL-27 on the activation of fibroblast-like synoviocytes in rheumatoid arthritis , 2010, Arthritis research & therapy.

[26]  J. Huibregtse,et al.  The ISG15 Conjugation System Broadly Targets Newly Synthesized Proteins: Implications for the Antiviral Function of ISG15 , 2010, Molecular Cell.

[27]  S. Akira,et al.  Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. , 2011, Immunity.

[28]  T. Iftner,et al.  Gene expression profiles reveal an upregulation of E2F and downregulation of interferon targets by HPV18 but no changes between keratinocytes with integrated or episomal viral genomes. , 2006, Virology.

[29]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[30]  B. Beutler,et al.  Intracellular toll-like receptors. , 2010, Immunity.

[31]  Lars Karlsson,et al.  TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. , 2007, Inflammation & allergy drug targets.

[32]  S. Bae,et al.  Prevalence of Human Papilloma Virus Infections and Cervical Cytological Abnormalities among Korean Women with Systemic Lupus Erythematosus , 2010, Journal of Korean medical science.

[33]  A. Bowie,et al.  Viral evasion and subversion of pattern-recognition receptor signalling , 2008, Nature Reviews Immunology.

[34]  T. Iftner,et al.  High-Risk Human Papillomaviruses Repress Constitutive Kappa Interferon Transcription via E6 To Prevent Pathogen Recognition Receptor and Antiviral-Gene Expression , 2011, Journal of Virology.

[35]  L. Tam,et al.  Activation profile of Toll‐like receptors of peripheral blood lymphocytes in patients with systemic lupus erythematosus , 2010, Clinical and experimental immunology.

[36]  David R. Scott,et al.  Improved Amplification of Genital Human Papillomaviruses , 2000, Journal of Clinical Microbiology.

[37]  M. V. Van Beek,et al.  Antimalarials , 2001, Dermatologic clinics.

[38]  Xuejun Liu,et al.  Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. , 2004, The Journal of clinical investigation.

[39]  G. Karypis,et al.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus , 2003, Proceedings of the National Academy of Sciences of the United States of America.